A tailored approach to value assessment will help drive innovation and impact patient outcomes and access to care, said Ilene Hollin, PhD, MPH, of the National Pharmaceutical Council.
A tailored approach to value assessment will help drive innovation and impact patient outcomes and access to care, said Ilene Hollin, PhD, MPH, of the National Pharmaceutical Council.
Transcript
Is a one-size-fit-all approach to value possible in US healthcare?
It’s not possible to have a one-size-fits-all approach to value assessment in the US healthcare system. We need a tailored approach, and to do so, this means that we need to understand, define, and measure value accurately, and then tailor our approach to the stakeholder, to the health condition, and to the subpopulation. This is imperative because there are substantial repercussions for reimbursement, patient access, and patient outcomes. It’s also important that we have a tailored approach because this is what will help drive innovation and make sure that future therapies are developed with what the patients want in mind.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Poor Well-Being Scores Linked to Early Treatment Stoppage in Multiple Myeloma
March 27th 2024Investigators used the Functional Assessment of Cancer Therapy-General General Physical Wellbeing Scale to collect data on patient-reported treatment-related adverse effects, to provide clinicians guidance on predicting risk of early treatment discontinuation among ECOG-ACRIN E1A11 trial participants.
Read More